Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) has been shown to have insulin-like effects upon the metabolism of glucose in rat liver, muscle and fat, and on that of lipids in rat and human adipocytes. These actions seem to be exerted through specific receptors which, unlike that of the pancreas, are not - at least in liver and muscle - cAMP-associated. Here we have investigated the effect, its characteristics, and possible second messengers of GLP-1 on the glucose metabolism of human skeletal muscle, in tissue strips and primary cultured myocytes. In muscle strips, GLP-1, like insulin, stimulated glycogen synthesis, glycogen synthase a activity, and glucose oxidation and utilization, and inhibited glycogen phosphorylase a activity, all of this at physiological concentrations of the peptide. In cultured myotubes, GLP-1 exerted, from 10(-13) mol/l, a dose-related increase of the D-[U-(14)C]glucose incorporation into glycogen, with the same potency as insulin, together with an activation of glycogen synthase a; the effect of 10(-11) mol/l GLP-1 on both parameters was additive to that induced by the equimolar amount of insulin. Synthase a was still activated in cells after 2 days of exposure to GLP-1, as compared with myotubes maintained in the absence of peptide. In human muscle cells, exendin-4 and its truncated form 9-39 amide (Ex-9) are both agonists of the GLP-1 effect on glycogen synthesis and synthase a activity; but while neither GLP-1 nor exendin-4 affected the cellular cAMP content after 5-min incubation in the absence of 3-isobutyl-1-methylxantine (IBMX), an increase was detected with Ex-9. GLP-1, exendin-4, Ex-9 and insulin all induced the prompt hydrolysis of glycosylphosphatidylinositols (GPIs). This work shows a potent stimulatory effect of GLP-1 on the glucose metabolism of human skeletal muscle, and supports the long-term therapeutic value of the peptide. Further evidence for a GLP-1 receptor in this tissue, different from that of the pancreas, is also illustrated, suggesting a role for an inositolphosphoglycan (IPG) as at least one of the possible second messengers of the GLP-1 action in human muscle.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · cited 3×
“…levels by not only enhancing pancreatic -cell secretion (Montrose-Rafizadeh et al. 1994) and diminishing blood glucagon and somatostatin concentrations (Gutniak et al. 1992), but also by acting independently of the circulating insulin levels (Gutniak et al. 1992, D’Alessio et al. 1994, 1995).”
BackgroundHenry, R. R., Abrams, L., Nikoulina, S., & Ciaraldi, T. P. (1995) · Diabetes · doi:10.2337/diab.44.8.936 · Cited by 233 · cited 1×
“The isolation of myoblasts was performed as described previously with minor modifications (Blau & Webster 1981, Henry et al. 1995).”
MethodCuendet, G. S., Loten, E. G., Jeanrenaud, B., & Renold, A. E. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108559 · Cited by 162
Lipolytic action of glucagon-like peptides in isolated rat adipocytes
Ruiz-Grande, C., Alarcón, C., Mérida, E., & Valverde, I. (1992) · Peptides · doi:10.1016/0196-9781(92)90134-o · Cited by 89
Self-citationGLP-1 (7-36) amide: Effects on glucose transport and metabolism in rat adipose tissue
Perea, A., Viñambres, C., Clemente, F., Villanueva-Peñacarrillo, M., & Valverde, I. (1997) · Hormone and Metabolic Research · doi:10.1055/s-2007-979068 · Cited by 53
Self-citation
Cited by
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
“Therefore, GLP-1 actions seem different from that in the pancreas (Galera et al., 1996; Trapote et al., 1996; Márquez et al., 1998; Yang et al., 1998; Luque et al., 2002).”
BackgroundPleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“This was observed in rat and human muscle cells, but also in studies conducted in hepatocytes and adipocytes, potentially utilizing inositol phosphoglycans (IPGs) as the intracellular second messenger (108, 110, 111).”
BackgroundGLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation
Shigeto, M., Ramracheya, R., Tarasov, A. I., Cha, C. Y., Chibalina, M. V., Hastoy, B., Philippaert, K., Reinbothe, T., Rorsman, N., Salehi, A., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81975 · Cited by 189
Iqbal, J., Wu, H., Hu, N., Zhou, Y., Li, L., Xiao, F., Wang, T., Jiang, H., Xu, S., Huang, B., et al. (2022) · Obesity Reviews · doi:10.1111/obr.13435 · Cited by 179
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
Halbirk, M., Nørrelund, H., Møller, N., Holst, J. J., Schmitz, O., Nielsen, R., Nielsen-Kudsk, J. E., Nielsen, S. S., Nielsen, T. T., Eiskjær, H., et al. (2010) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00930.2009 · Cited by 165
“Some in vitro (13) and animal (9) studies indicate an immediate insulin sensitizing effect, but we could not confirm this effect in these patients.”
BackgroundPerna, S., Guido, D., Bologna, C., Solerte, S. B., Guerriero, F., Isu, A., & Rondanelli, M. (2016) · Aging Clinical and Experimental Research · doi:10.1007/s40520-015-0525-y · Cited by 125
Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
León, D. D. D., Crutchlow, M. F., Ham, J.-Y. N., & Stoffers, D. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.07.011 · Cited by 94
Effect of GLP-1 on glucose transport and its cell signalling in human myocytes
González, N., Acitores, A., Sancho, V., Valverde, I., & Villanueva-Peñacarrillo, M. L. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.10.002 · Cited by 85
Self-citationGreen, C. J., Henriksen, T. I., Pedersen, B. K., & Solomon, T. P. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044284 · Cited by 80
Takada, S., Masaki, Y., Kinugawa, S., Matsumoto, J., Furihata, T., Mizushima, W., Kadoguchi, T., Fukushima, A., Homma, T., Takahashi, M., et al. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw182 · Cited by 78
Recent advances in understanding the role of glucagon-like peptide 1
Reed, J., Bain, S., & Kanamarlapudi, V. (2020) · F1000Research · doi:10.12688/f1000research.20602.1 · Cited by 66
Li, Z., Ni, C.-L., Yao, Z., Chen, L.-M., & Niu, W.-Y. (2014) · Metabolism · doi:10.1016/j.metabol.2014.05.008 · Cited by 56
GLP‑1 improves palmitate‑induced insulin resistance in human skeletal muscle via SIRT1 activity
Jeon, J., Choi, S., Ha, E., Lee, H., Kim, T., Han, S., Kim, H., Kim, D., Kang, Y., & Lee, K. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4272 · Cited by 33
Metadata
- Authors
- Luque, M., Gonzalez, N., Marquez, L., Acitores, A., Redondo, A., Morales, M., Valverde, I., & Villanueva-Penacarrillo, M.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2002-06-01
- Volume
- 173
- Issue
- 3
- Pages
- 465-473
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2096045658
- Cited by
- 131
- References
- 6
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.